The Association of Clinical Research Professionals (ACRP) is proud to recognize Pfizer as a Breakaway Sponsor of the 2023 ACRP Ride4DEI for Clinical Research Workforce Diversity.
The ACRP Ride4DEI is the clinical research industry’s premier cycling challenge that raises funds in support of ACRP educational scholarships—including attendance at ACRP’s annual conference—for entry-level clinical research professionals from diverse communities. Every dollar raised will help increase access to education, training, and career advancement in clinical research for people from historically underserved communities.
“We know that the more diverse the clinical trial workforce, the more diverse the clinical trial participant population,” says Susan Landis, ACRP Executive Director. “In addition to regulatory guidance encouraging trial participant diversity, ACRP can build a diverse, research-ready workforce through programs that provide access to training to enter and advance in the clinical research profession. We are incredibly thankful for Pfizer’s support of the ACRP Ride4DEI—whose contribution goes directly to this goal.”
“Pfizer is proud to sponsor ACRP’s Ride4DEI once again,” said Sandra Amaro, Head of Clinical Trial Diversity at Pfizer. “We applaud ACRP’s efforts to expand the pool of clinical research professionals. It is efforts like these that we believe can help increase diversity in clinical trials and ensure that historically underserved communities have access to research and ultimately benefit from medical breakthroughs.”
In 2022, more than 80 individual and corporate donors contributed $63,675 in donations to fund the ACRP Ride for Diversity, a 6-day, 355-mile grueling bike ride from Pittsburg to Washington, DC. The funds supported more than 20 scholarships to ACRP’s annual conference, as well as development of ACRP’s ‘Ready, Set, Clinical Research!’™ toolkit designed to support stakeholders with a vested interest in the growth and diversification of the clinical research workforce. The fundraising goal for 2023 is $120,000.
“As the leading workforce association for the clinical research industry, ACRP has a responsibility to ensure that all people—regardless of race, ethnicity, religion, or orientation—can embark on a career in clinical research and advance without prejudice. My hope is that the ACRP Ride4DEI will continue to raise money for much needed scholarships and serve as a catalyst for clinical researchers who desire greater access to career opportunities,” says Sergio Armani, EVP, Business Development, Helios Clinical Research, and ACRP Ride4DEI creator.
“The ACRP Ride4DEI is a demonstrative, actionable initiative supporting advancement and accessibility for the clinical workforce,” says R’Kes Starling, RPh, MBA, ACRP Diversity Advisory Council Leader, and CEO/Founder, Reveles Clinical Services. “Increasing diversity in hiring of clinical researchers improves diversity among clinical trial participants, healthcare access, and equity of care.”
With more than 13,000 members, the Association of Clinical Research Professionals (ACRP) is the only non-profit organization solely dedicated to representing, supporting, and advocating for clinical research professionals. ACRP supports individuals and life science organizations globally by providing community, education, and credentialing programs. Founded in 1976, ACRP is a registered 501(c)(3) charitable organization whose mission is to promote excellence in clinical research and whose vision is that clinical research is performed ethically, responsibly, and professionally everywhere in the world. Follow ACRP on LinkedIn, Facebook, Twitter, Instagram, and YouTube. Learn more by visiting acrpnet.org. Advancing People Advancing Health™
Breakthroughs That Change Patients’ Lives: Pfizer is a leading research-based biopharmaceutical company. They apply science and global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. To learn more, visit pfizer.com.